Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec 31;38(4):462-471.
doi: 10.23876/j.krcp.19.053.

Protective effects of D-005, a lipid extract from Acrocomia crispa fruits, against ischemia/reperfusion-induced acute kidney injury in rats

Affiliations

Protective effects of D-005, a lipid extract from Acrocomia crispa fruits, against ischemia/reperfusion-induced acute kidney injury in rats

Ambar Oyarzábal-Yera et al. Kidney Res Clin Pract. .

Abstract

Background: Acute kidney injury (AKI) induced by renal ischemia/reperfusion (IR) is associated with enhanced production of reactive oxygen species in renal tissues. D-005, a lipid extract obtained from Acrocomia crispa fruit, has previously shown antioxidant effects. The aim of this work was to evaluate the effects of D-005 on renal IR-induced AKI in rats.

Methods: Rats were randomized into seven groups including a negative control group (vehicle) without AKI and six groups with renal IR-induced AKI as follows: a positive control (vehicle); D-005 treatment at 25, 100, 200, or 400 mg/kg; and dexamethasone at 3 mg/kg. All treatments were orally administered as single doses 1 hour before AKI induction. Biomarkers (serum creatinine, urea, and uric acid concentrations), oxidative variables, and histopathological AKI changes were evaluated in blood and kidney tissues.

Results: All D-005 doses protected against IR-induced AKI in rats by significantly decreasing biomarkers and histopathological AKI changes as assessed by reduced serum concentrations of creatinine, urea, and uric acid. In addition, all D-005 doses decreased tubular damage, as shown by fewer detached cells and casts in the tubular lumen. D-005 reversed oxidation disturbance markers by decreasing malondialdehyde and sulfhydryl group concentrations in plasma and in kidney homogenates and by increasing kidney catalase activity. Dexamethasone, the reference substance, protected against IR-induced AKI in rats by reducing biochemical and histological variables of renal damage in a similar manner.

Conclusion: Administration of single oral doses of D-005 markedly and significantly protected against renal IR-induced AKI, possibly due to its known antioxidant effects.

Keywords: Acrocomia crispa; Acute kidney injury; D-005; Rats; Renal ischemia/reperfusion.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

All authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Effects of D-005 on serum creatinine concentrations in rats with IR-induced acute kidney injury. Data are presented as mean ± standard error. *P < 0.05, ***P < 0.001, compared to the positive control group (Mann–Whitney U test). DEX, dexamethasone; IR, renal ischemia/reperfusion.
Figure 2
Figure 2
Effects of D-005 on serum uric acid concentration in rats with IR-induced acute kidney injury. Data are presented as mean ± standard error. *P < 0.05, **P < 0.01, ***P < 0.001, compared to the positive control group (Mann–Whitney U test). DEX, dexamethasone; IR, renal ischemia/reperfusion.
Figure 3
Figure 3
Effects of D-005 on serum urea concentration in rats with IR-induced acute kidney injury. Data are presented as mean ± standard error. ***P < 0.001, compared to the positive control group (Mann–Whitney U test). DEX, dexamethasone; IR, renal ischemia/reperfusion.
Figure 4
Figure 4
Renal cortex of Sprague-Dawley rats. (A, B) Negative control, (C, D) positive control, (E, F) D-005 25 mg/kg, (G, H) D-005 100 mg/kg, (I, J) Dexamethasone 3 mg/kg. A, C, E, G, and I: periodic acid-schiff staining, 100 μm. B, D, F, H, and J: 50 μm. *, hyaline cast; NC, necrotic cells; PT, proximal tubules.
Figure 5
Figure 5
Effects of D-005 on tubular damage in rats with IR-induced acute kidney injury. Data are presented as mean ± standard error. *P < 0.05, **P < 0.01, compared to the positive control group (Student’s t test). DEX, dexamethasone; IR, renal ischemia/reperfusion.
Figure 6
Figure 6
Effects of D-005 on plasma concentration of malondialdehyde (MDA) in rats with IR-induced acute kidney injury. Data are presented as mean ± standard error. *P <0.05, **P < 0.01, ***P < 0.001, compared to the positive control group (Mann–Whit-ney U test). DEX, dexamethasone; IR, renal ischemia/reperfusion.
Figure 7
Figure 7
Effects of D-005 on plasma concentration of sulfhydryl (SH) groups. Data are presented as mean ± standard error. *P < 0.05, **P < 0.01, compared to the positive control group (Mann–Whitney U test). DEX, dexamethasone; IR, renal ischemia/reperfusion.
Figure 8
Figure 8
Effects of D-005 on malondialdehyde (MDA) concentration in rats with IR-induced acute kidney injury. Data are presented as mean ± standard error. *P < 0.05, **P < 0.01, ***P < 0.001, compared to the positive control group (Mann–Whitney U test). DEX, dexamethasone; IR, renal ischemia/reperfusion.
Figure 9
Figure 9
Effects of D-005 on sulfhydryl (SH) group concentration in rats with IR-induced acute kidney injury. Data are presented as mean ± standard error. *P < 0.05, **P < 0.01, compared to the positive control group (Mann–Whitney U test). DEX, dexamethasone; IR, ischemia/reperfusion.
Figure 10
Figure 10
Effects of D-005 on catalase (CAT) activity in rats with IR-induced acute kidney injury. Data are presented as mean ± standard error. *P < 0.05, ***P < 0.001, compared to the positive control group (Mann–Whitney U test). IR, ischemia/reperfusion.

References

    1. Hobson C, Lysak N, Huber M, Scali S, Bihorac A. Epidemiology, outcomes, and management of acute kidney injury in the vascular surgery patient. J Vasc Surg. 2018;68:916–928. doi: 10.1016/j.jvs.2018.05.017. - DOI - PMC - PubMed
    1. Nie S, Tang L, Zhang W, Feng Z, Chen X. Are there modifiable risk factors to improve AKI? Biomed Res Int. 2017;2017 doi: 10.1155/2017/5605634. 5605634. - DOI - PMC - PubMed
    1. Sawhney S, Fraser SD. Epidemiology of AKI: utilizing large databases to determine the burden of AKI. Adv Chronic Kidney Dis. 2017;24:194–204. doi: 10.1053/j.ackd.2017.05.001. - DOI - PMC - PubMed
    1. Ratliff BB, Abdulmahdi W, Pawar R, Wolin MS. Oxidant mechanisms in renal injury and disease. Antioxid Redox Signal. 2016;25:119–146. doi: 10.1089/ars.2016.6665. - DOI - PMC - PubMed
    1. Agarwal A, Dong Z, Harris R, et al. Acute Dialysis Quality Initiative XIII Working Group. Cellular and molecular mechanisms of AKI. J Am Soc Nephrol. 2016;27:1288–1299. doi: 10.1681/ASN.2015070740. - DOI - PMC - PubMed

LinkOut - more resources